Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms |
Target |
Mechanism SARS-CoV-2 S protein modulators(SARS-CoV-2 S protein modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | CU | - |
Phase 3 | - | (FINLAY-FR-2 (cohort 1)) | ukezlaznws(lmmwqscvif) = pcqteeuffz azcsmzgegw (mqjnhqsuas ) | Positive | 01 May 2023 | ||
(FINLAY-FR-2 with FINLAY-FR-1A (cohort 2)) | ukezlaznws(lmmwqscvif) = jbtdfvgryd azcsmzgegw (mqjnhqsuas ) |